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Mr-rch is known about the pathophysiology of atherosclerosis and its risk factors. Best
knorvr.r traditional risk frrctors include age and gender. At a certain distance these flrc-
tors are fo l lowed by smoking,  hyperter . rs ion,  dys l ip idaemia and d iabetes.
Furthermore, ncln-traclitional risk Íirctors are emerging, such as elevated rrpolipopro-
tein l i, hornocysteine, frbrinogen, lp(a), HS-(IRP (high selective C-reactive Proteir.r),
Lp-PLA, (l ipoprotein-associatcd phospholipase A2) and elevated rnarkers of ir.r-
f lamrnation such as interleukine 6, sICAM- I (soluble intercellular adhaesion mol-
ecule), serum Arnyloid A, solulrle CD40 ligand and neopterin.
In Chaptcr / a short overview concernir.rg the patho-physiological background of
atherosclerosis is presentcd as well as a detailed overview concerning l ipid-lowering
therapy after acute coronirry syndrome and the value of honrocysteine lolvering
therapy in patients rvith stable coronary artery disease.
Chopter 2 deals with the added value of apolipoprotein B (apoB) for daily prac-
tice. ApoB is a protein which is integrated in the membrane of both chylornicrons
(and its remnirnts) as well as VLDL (and its remnants such as IDL and LDL). In
general, plasn.ra poB is dominatecl by the protein that is bound to VLDL irnd its rem-
nants due to tl.re relative short resident irne of chylomicrons in the circulation.
The apots molecule which is coupled with VI,DL ar.rd its remnant particles is called
apot} 100 as opposed to apoB48, which is coupled to chylornicrons and its rem-
nant particles. As every VLDL remnant particle is attached to one apoB ntolecule,
plasn.ra apolS level provides more information on the amount of atherogenic par-
ticles than LDl. level does. At a sin.ri lar LDL-(l level, at a low apoB-value one has tc'r
do with iarge br,royant LDL particles, whereas at a high apoB value, one encolln-
ters small dense LDL particles. Srnall dense LDL particles in particular appear to be
extremely atherogenic. In addition, these particles appear more frecluently in patients
r'vith the so-called metabolic syndrome of which insulir.r resistance makes an intri-
cate part of. l ' l-r is may explain, at least in part, the higher occllrrence of premature
atherosclerosis n patie nts with r.r.retabolic syr.rdrome. Nloreover, the I'alue of apoB
as ir risk indicator beccnres increasingly powerful when combinecl with apoA1, the
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apolipoprotein attached to HDl.-(l particles. Thercfbre, the ratio apolS/Al can be
consiclered as orte of the l.nost potent indicators of carcliovascular risk. In additictn,
there is itrcrcasit.ts cviclence that apoB n'right be a bcttcr target for cholestcrol lou,-
ering therapy than fbr instance LDL-cholcstcrol or non-HDL cl.rolesterol.
Comments and future devel()pments
Fttr tvitle dcc('ptturce atrd applicatiort o.f trteonrrt'ntt'rtts of apolipoproteirrs irr daily prac-
tict 'tht'rc ls -solre rreccssity to (rt ')dc.fint'rtttntral yalues i ltd provide risk algorithtrrs
srrc/i rrs alreatly cxistírrg.for chttlcstertt l (or clrole stcrol/Hl)1. ratio).
Choptcr j deals rvith lorv high clensity l ipoprotcin cholesterol (Hl)L-C) rvhich is
fiecluentlv errcounterecl in paticr.rts rvith carcliclvascular discase. In cornbinatior.r
n'ith elevated triglycerides, lolv-HDL-C is ofien cncountcrecl in patients rvith the
n-retabolic svttdrome.'l ' l .r is syndronre is also chararcterizcd by cler,atecl apolipopro-
te in 13, irs has been Ilentioned in chaptcr 2. Considering tl.re valuc of statin therapy
it I 'ras b be statecl that no ft lrnral secondary prevcntion trials hirvc bcen carriecl out
in specific populations r'r, ith lorv HDL-(1. Horvevcr, sub-analysis of thc l inorvr.r large
statin itrtervention trials indicate that statin is at least as eÍ1èctivc in patients rvitl.r lorv-
versus pntiettts rvith a normal HDl.-C level. Adclit ionally, trials rvith Ílbrate tl.rer-
apf in seconclary prevcntiotr have bee n positive in populirt ions r.vith lolv HI)L (l
albeit nornral LI)L-(1. Therefore, it seems logical to introcluce a lorv thresholcl for in-
stittrtirtg a contbirtirtion therapy of strrtins and flbrates. hrdecd, tl-ris combination has
been proven to be effective in reclucing Ll)L-Cl, apoB and triglycericles ancl at thc
sarne tirrc this con'r[rination gives rise to significant increase of HDL-(]. Hor,vcver,
ttp ti l l  rtorv no data from htrrcl cl inical cr"rdpoir.rt stuclies upport this con.rbination
therapy. Moreovcr, tl'ris conrbination is r.rot fl'ee frotn risk, especiirlly of increased risli
of n.ryopathy.
'fhcrefbre, 
orte first has to explore other rneirr.rir.rgful contbination thcrapics
rvhich i t re ev idence-bi rsed such as conrbinat ion thcrapy of  s tat ins i r r rc l  A( lE- in-
hibitors. Fispecially in the HOPE triarl this cornbination has been proven to havc
acldit ive valuc. Anothcr aclvantirqe of this cornbinatior.r is the Írrct that ACE-in
hibitors arc especially indicatcd in patients with the rletabolic syndron.rc.
Cornnrcnts and future developments
Itt t lrc Jirttrre it is t lesirable Ío pttri l te devcloptncrrts oJ-rrtedicatiotr lvith at:ccptdtlc tol
erottce, which rrctt only eJflctivcly rcdttces LDl.-C level, but alstt irrcreases Hl)L-C lcvel.
Howevt'r, ot tltc sonrc tirrrc ctrrc lns to irrvcstigate if plnrmacologicol clevatiort ol HDL-
C will lcttd ttt rerhtcetl risk. lrr odditiotr, it is still relt:vartt to contnrcncc studics of stotirr
and lt ltratc cotrtbitnliorrs tvith hard clinical outconrcs. Furtlrerntore, it wil l be wel-
cttntcd if tlrc isnrc of low HDL-C is not ottly regardcd s Lt seporote ntity os it sttrtrc-
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tinrc is, but will ako be int estigated as a part of the metabolic syndrome because the com
binatiorr of low-HDL-C and metabolic syndrome is frequently encountered in daily
practice. [n adtl it ion, intervcntion in paticnts with metabolic syndrome should not
only focus on lipid parttrneters, btft ntainly on reduction of risk.
At the time the FLORIDA study was designed (Chapter 4) little was known about the
value of statin therapy in the semi-acute phase of myocardial infarction (Ml).
Especially the right tirne to start therapy is a controversial one. Most experts and
guidelines advise to start therapy to 1 year after MI and overtime this period
gradually decreases to 3 months. Mar.ry studies were designed to resolve this issue.
The FLORIDA study was set up as a rnechanistic study, questioning whether early
statin treatmer-rt following a myocardial infarction could diminish myocardial is
chemia rneasured with 48-hor.rrs Holter monitoring. This stuclv could not confirn-r
this hypothesis.
Comments and future developments
On the basis of data presented in literature it seems that ischenia after MI is a frequent
finding. These dattt determined the size of the study population of the Florida trial.
However, aftertvards it became vident that residual ischemia in this day and age be-
catne a rather seldom finding due to increasing use of anti-ischemic therapy (invasive
and non-invasive). In order to conJirm reduction in ttn eyent that occurs infrequently,
one needs fasts nuntbers oJ'patients to investigate. I'hese ancl other factors are con
sidered in an occompttnied editorial However, the Florida study did confirm that
residtral ischenitt after MI remains a prognostic factor for the development oJ'clinical
events.
What is the current policy regarding commencing oJ- cholesterol lowering nredication af-
ter an dcute coronary syndrome (ACS) ? Most current gttidelines now adyise statirr
therapy Lrs oon as possible. This advise is also based on the lact that firstly, it is not
harmftil and seconclly, it pret ents forgetting the installment of therapy. In addition, it
has been shown that starting statin therapy in the hospital enhttnces the medical corn-
pliance on the long run.
The ovttilability of clinical evidence on the basis oJ'epideniological obseryations and
intervention studies is meticulously described in the introdtLction section (chapter 1). In
summory it can be stated that availability of hard clinical evidence is still limited and
thereJ'ore the resubs of ongoing stttdies like the A-Z study should he awttited.
Chapter 5 deals with the value of inflammatory markers as risk ir.rdicator after a
non-Q-wave rnyocardial infarction (NQWI).' l 'his has been investigated in a sub
population of the FLOI{lDA trial. As markers of inflammation, CRP and neopterin
were used. Neopterirr reÍ lccts nronocytc/macrophaee interaction as a result of in-
tcrferon-y production by irct ivated ' l  - lynrphocytes. I t  appearecl that neopterin ir loue
its nel l  ars in conrbinaticln rvith HS (l l {P hacl a irrecl ict ir ,e valuc tbl i rcl t 'crse outconrc
a l t c r  N Q W I .
Comnrents and future developnents
It n,otr ld bt '  desintble i . l  in t l rc rrcar.f i r t t tre irr . l larrtntatory rrrarkcrs rtukt 'part oJ t lrc cl irr
ictr l  cvaltnt ictn o. l 'pal icnts who rccgrtLl '  ( ' . \peri(t tced r ln ACS. ' l ' l te cottte rrtpt)rar),  ds-
suttlptiott is, thot thesc rnorlrcrs dtt not only reJlcct activc irr.llamrrtatiotr at tlrc sitt'of tlrc
ctr lpr i t  Icsiotr btt l  olso re.t ' lcct t l t t '  i r t tertsi ty o. l ' t l tc atht 'rosclt ' r t t t ic 1>rot:css irr ccneral. ' l ' l tc
latter cttn tspeciul ly bt ' in.f l t turccd by systt ' tr t íc trcí l t t l rctt t .  Srt l tscqLrerrt l l ' ,  t l tc.f i t l lotvi tr t
tlttcstiotrs rtt'cd to be addressad: shLtuld systctrtic tlrcralty bc loctrscd ttrr redrrctiort oJ tltc
ttrorkt 'rs, dot 's rcdtrct iort oJ'thesc rt tarkt 'rs lctrd t t t  radrrct iotr o_l '  r isk artd ctt tr  l l test,  trrark
t 'rs bc trsetl  i rr  r isk stratí l i t :ol ion ? AIsLt, onL'sltotr ld qttcst iotr wlrcl l ter í l rc dctcrrrt i tr t t t i r t tr
o. l '  inJlonutratory trutrkcrs L-ttrr t :orttr ibtÍe to nutdulat irryl troad prevt,rrt ivt '  rncdit 'ot iorr
(trspir ir t ,  clopidotrel,  oral orrt icLtttgt i lal iort,  -slaÍ ir-s, bt ' ta blot:kcrs, A(.8 i trhi l t i tors,, t t t-
gicttetrsirre-racepÍor-blockcrs etc.) to strch tr t lc{ree l l rot rrt t t  c1,1,y1, f t4t iertt  tyi l l  artto,
rrrtrticrilly bt' treott'd witlt this extcrtdetl rtrcdimtiorr, but lct tt dccreL' at wlritlr it is crttluirt,tl
wlr icl t  poti t ' t r t  rcol ly rtcetls t lnt t trul 
. f t tr  l t t tr . ,  lotrg,.
Fol lorving chaptcrs concenr stucl ies reganiing the subject of hontoo.stcine. At the
tinre oÍ 'designing thc FOLARI)A study (cho]) lcr ó) I .ronrocysteinc started to fulf l l
thc rolc of cmeruing r isk f irctor. Obscrvirt ional cl ir ta cspccial ly poirrtcd in the cl irec
t ion of hontocvsteine as irn inrportant r isl i  fàctor, rvhich bccan-re thc reasorr f i rr  the
rlcsign of thc FOl.Al l . l )A as i l  pi lot sttrcly. I t  concerned a nrult i  ccntcred, ranclor.r.r isccl
tr ial  rvi t l .r  an opcn labcl 5 nrg Íbl ic acid intcnentiorr in ir  higir r isk populat ion in thc
f irrm of post A(iS patie nts n, i th an elu,atccl cholestcrol lcvcls. [ . i teratulc shorvs that
f ir l ic acicl l ' ras both direct beneÍlcial characterist ics fbr artery wtr l ls as rvcl l  as indi
rcct ef lccts lry lolvering hor.t . tocysteinc valr.re. ln al l  283 patients st ir t in therapy r,virs
in i t ia tcc l .  I t  tunrcc l  o t r t  t l ' ra t  hard  c l in ic i r l  enc lpo in ts  in  the  f i r rn r  o f  usua l  N lACl l
(Mqor Advcrse ( lardiovascular Endpoints) occurrccl just as often in thc fol ic acicl
trcl tecl sroup .1s in thc control group (both 3l(Xr) cluring one ycirr ol '  Í t l l lorv-up. This
s t t rc lvc rea tcc l  thcover tu rc f i r ra la rger i r t tenent ions tudr , , the  ( i rcss tnc l r .  (c lnp tc rT) .
Thc GOHS stucly incluried pirt icnts wit l .r  stable corouarv artery diseasc, ur con-
tracliction to thc I-OLARDA stucly in rvl-rich paticnts w'ith ir recent nryocarciial inf:rrct
u,cre incluclecl.  ()thel cl i f lcrenccs u'cre f<trr-necl as t l tc ( loes stLrdy is an ur-r i-ccr-rtcr '
tr ial  rvi th irrr intcrvention of fol ic: icicl  0.5 nrg. ( in contrat l ict ion to 5 ms in thc FO-
I.Alt l)A). A lor.vcr closcs fbl ic acicl rvr is choscn, rrs sel,cral l i rcts point to aclcquirte et l
Íèct iveness of this dosage in orcler to lclr ' r ,er honrocysteinc, ancl becunse this closagc
stauds closer to the anrotrnt uscd as cl ietary suppleurents. Furthernrore, au inrp()r





































participate who were :rlready r,rsing statir.r therapy. The study size was deterrnir.red on
basis of then availirble pidenriological data. 593 Patients were inch-rded in the study;
300 were randonrised to folic acid treatr-ncnt and 293 served as controls. Mean fol-
low-up tinre amountecl two years.
F'rom tl.ris study it appeared that folic acid could indeed reduce I'romocysteine val
ues. However, tl.ris was not combined with :r den.ronstrable recluction of the occur-
rence of MACE (10.3(/o in the treatmeut grolrp ancl 9.6 7o in the control group;
RR L05; 95 7o CI: 0.63 1.75). Yet, in univariate analysis, the baseline value of ho-
rnocysteir.re did point out to have a predictive value for MACE; however, the base-
line virlue of homocysteine was irrelevant wher-r creatinine clearance in rnultivari-
ate analysis was incorporated. lt even appeared that thc value of creatinine clearance
was one of the nrost powerful preclictors for MACE, followed by the level of fib-
rinogen. In this study fibrir.rogen was determined as a pararneter Íbr inflamr.n;.rt ior.r
as wcl l  as l i r r  throrn l rogerrec i ty .
Comments and future developments
First of all, it is inrportant o ascertaitt thnt the prrtgnostic valuc of honrocysteine Jór thc
developntcnt of cnrdiovnscular diseases i ntore linited thatt it would appcar to be on
first sight. Pttblicatiort bias is certoirrly to blamc for thís. Ncverthcless, cspecially re-
cent tneto-analyses assign un unobtrusíve rolc to hornocysteine tts a rísk nrorker.
TlrcrcJbrc, ltasetl on rccent data rcgrtrding folit: acid intervention one should ltase
oncsclf otr the assuntption o.l-risk retluctictns of 1 I to a nmxintum of 20 o/o rathcr than
of 50 % stttJt as srrgges/crl earlier, at least concening ischaetnic heart diseases.
Mnreover, it is notcworthy that in epidentiobgical literahtre honrocysteine is seldont
corrccted by rertal furtctiott. At arty rate, sonrctinrcs orily tt correctiort is trnde Jor thc
serutn crcotinina valuc. Howcver, irr the clinic it is wall-known that calt-ttlated creati-
nirrc clearonce is a nuclt bettcr intlicator J'or reml furrction tltat thc serrurr crentininL'
yoltrc. Moreot,er, renol ftmction.fitlJik a crucial role irr the nrctabolism artd clettrancc
of lutntocysteine. Therel'ore, it is rtot ruled out tlnt honrocysteirrc nrcrely reJlects litnitetl
renal furrction and tltot l inrited renal Jilnction in its turrt is a reJTcction of thc
extertsiverrcss oJ'the atherosclcrotic process. The latter is certttinly oJ.progrtostic inrpor-
tnrrcc.' l 'hcreforc, egardingtlris corrsiderntion it is tncerttt in whether folic acid inter-
vention can lentl to risk reduction ond if this is the casc, it rt ight omount to less than
the predictcd 11 to 20 %t. Cttrrent rcsettrclt has to give o decisive ansrver belitre Jblic ot:id
sultstitution becLtmes o stantlard advice to pdticnts with establishcd cardiovoscular
discase.
